Weight management is often described as a matter of reaching a target. But for many people, the harder question comes afterward: What helps maintain weight loss over time?
Two follow-ups to clinical trials of newer weight-loss medicines offer one answer, and an important caution. In the studies, participants who stopped treatment regained a substantial portion of the weight they had lost, on average. The findings suggest that maintenance deserves attention from the start—but they do not predict what will happen to every person, or show that one approach is right for everyone.
What happened after treatment stopped
In the SURMOUNT-4 trial, adults with obesity or overweight and a related health condition first received tirzepatide for 36 weeks, alongside lifestyle counseling. On average, participants lost about 21% of their starting weight during that period. Researchers then randomly assigned participants either to continue tirzepatide or to switch to a placebo for 52 weeks. Lifestyle counseling continued in both groups.
During the second phase, the group that continued the medicine lost an average of another 5.5% of its weight. The group switched to placebo gained an average of 14.0% relative to its weight at the start of that phase. In a separate follow-up of the STEP 1 semaglutide trial, participants regained about two-thirds of their earlier weight loss, on average, during the year after treatment and trial lifestyle support ended.
These are group averages, not individual forecasts. The trials also studied particular medicines, participants and follow-up periods. SURMOUNT-4, for example, randomized people after they had completed a 36-week medication period; its results may not represent everyone who considers or starts treatment.
Maintenance is part of treatment
The findings challenge the idea that weight-loss medication is necessarily a brief course that ends once a number on the scale changes. They point instead to the importance of discussing maintenance as part of care: what support may continue, what options exist if a medicine is stopped, and how health goals will be followed over time.
That discussion is individual. The FDA approved tirzepatide under the brand name Zepbound for chronic weight management in eligible adults, used with a reduced-calorie eating plan and increased physical activity. Whether medication is appropriate depends on a person’s health, preferences, risks and access to care. A clinician can help weigh those factors and discuss alternatives or a plan for changes in treatment.
Weight regain after stopping a medicine is not proof of a lack of effort. The studies show what happened on average in specific trial settings; they do not establish a person’s motivation or explain every individual outcome. Weight management can involve ongoing care, and progress can include health measures and daily functioning—not only body weight.
For anyone considering treatment, a useful question may be less “How quickly can I lose weight?” and more “What would support my health and help me maintain progress over time?” These trials do not settle that question. They do make the follow-up plan harder to overlook.
